問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Study Statistics

5306Cases

20022027

Total

5306

  • I

    571

  • I/II

    251

  • II

    1223

  • II/III

    136

  • III

    2605

  • IV

    105

  • Others

    354

Principal Investigator

2768Doctors

Co-Principal Investigator

8931Doctors

Hospital

125Sites

List

5306Cases

2025-10-01 - 2030-12-24

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2025-10-01 - 2028-04-30

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2026-07-01 - 2030-06-30

Phase III

Not yet recruiting
A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs

  • Condition/Disease

    Psoriatic Arthritis

  • Test Drug

    錠劑

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2025-10-15 - 2028-10-31

Phase II

Not yet recruiting
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2026-07-01 - 2028-12-31

Others

Active
A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)Metastatic Breast Cancer

  • Condition/Disease

    Metastatic Breast Cancer

  • Test Drug

    膜衣錠 膜衣錠 預充填式注射劑 膜衣錠 膜衣錠 膜衣錠 膜衣錠 持續釋放膜衣錠 膜衣錠

Participate Sites
2Sites

Not yet recruiting2Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB